(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1561499

組換えDNA技術市場レポート：製品、コンポーネント、用途、エンドユーザー、地域別、2024年～2032年

Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 139 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
組換えDNA技術市場レポート：製品、コンポーネント、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の組換えDNA技術市場の市場規模は2023年に7,648億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて4.1%の成長率（CAGR）を示し、2032年までに1兆1,190億米ドルに達すると予測しています。遺伝子工学やバイオテクノロジーの進歩、バイオ医薬品に対する需要の高まり、個別化医薬品へのシフトの増加、慢性疾患の有病率の上昇が、主に市場の成長を牽引しています。

市場規模 年平均成長率（CAGR）グラフ | 組換えDNA技術市場レポート：製品、コンポーネント、用途、エンドユーザー、地域別、2024年～2032年

組換えDNA技術市場分析：

  • 主な市場促進要因：診断キット、モニタリング機器、新たな治療アプローチの開発による治療戦略の改善と相まって、さまざまな健康状態の改善に対する需要が高まっていることが、市場の成長を促す主な要因の1つとなっています。
  • 主な市場動向：急速な都市化、世界人口の増加、耕地の減少、食糧不足の深刻化、遺伝子組み換え作物の採用増加などが、市場の需要を高めています。さらに、組み換えDNA技術と、欠陥遺伝子を正常な遺伝子に置き換える効果的な遺伝子治療の融合、臨床研究、調査、疾病診断のための抗原特異的抗体の生産が、今後数年間の市場成長を促進すると予想されます。
  • 競合情勢：著名な組換えDNA技術市場企業には、Amgen Inc、Cibus、F.Hoffmann-La Roche Ltd、GenScript、GlaxoSmithKline plc、Horizon Discovery Group plc、Merck KGaA、New England Biolabs、Novo Nordisk A/S、Pfizer Inc、Sanofi S.A、Syngene International Ltd（Biocon Limited）などがあります。
  • 地理的動向：組換えDNA技術市場のダイナミクスによると、北米は広範な研究開発活動、確立されたヘルスケアインフラ、政府からの多額の資金提供により、組換えDNA技術市場で顕著なシェアを占めています。さらに欧州の成長は、研究開発への強い注力とバイオ医薬品の高い採用率に支えられています。
  • 課題と機会：規制の強化や主要企業間の競合の激化が市場成長の妨げとなっています。しかし、環境に優しく燃料効率の高い着陸装置システムに対する需要は増加しています。メーカーは、軽量素材やエネルギー効率の高い設計を開発することで、この動向を利用することができます。

組換えDNA技術市場動向：

バイオ医薬品需要の高まり

モノクローナル抗体、ワクチン、インスリンなどのバイオ医薬品に対する需要の高まりは、主要な促進要因です。例えば、IMARCによると、世界のバイオ医薬品市場規模は2023年に3,005億米ドルに達しました。今後、IMARCグループは、2032年までに同市場が6,439億米ドルに達し、2024～2032年の成長率（CAGR）は8.6%になると予測しています。組換えDNA技術は、様々な慢性疾患の治療に不可欠なこれらの製品の生産において極めて重要です。これらの要因は、今後数年間、組換えDNA技術市場を推進すると予想されます。

慢性疾患の有病率の増加

がん、糖尿病、心血管疾患などの慢性疾患の有病率の増加は、市場の成長を促す重要な要因の一つです。例えば、IDF Diabetes Atlas（2021年）によると、20歳から79歳の成人の10.5%が糖尿病を患っています。また、2045年には8人に1人、およそ7億8,300万人が糖尿病に罹患することになり、これは46％増に相当します。組換えDNA技術は、糖尿病管理のためのインスリンや貧血治療のためのエリスロポエチンなど、必要不可欠な治療用タンパク質やホルモンの生産を可能にします。これらの要因は、組換えDNA技術産業市場にさらにプラスの影響を与えています。

技術的進歩

CRISPRやその他の遺伝子編集ツールなど、絶え間ない技術革新が組換えDNA技術の精度と応用範囲を高め、市場拡大を促進しています。例えば、2024年8月、ドイツの研究者グループは、血液腫瘍と固形腫瘍の両方を標的とするCAR-T細胞療法における既存の障害を解決し改善するために、強化されたCRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）技術を開発しました。CRISPRは、遺伝学者や医学研究者がDNA配列を除去、挿入、変更することでゲノムの一部を編集することを可能にするユニークな技術であり、組換えDNA技術システム市場の収益を押し上げます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の組換えDNA技術市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 医療
    • 市場動向
    • 主要セグメント
      • 治療薬
      • ヒトタンパク質
      • ワクチン
    • 市場予測
  • 非医療
    • 市場動向
    • 主要セグメント
      • バイオテクノロジー作物
      • 特殊化学品
      • その他
    • 市場予測

第7章 市場内訳：コンポーネント別

  • 表現システム
    • 市場動向
    • 市場予測
  • クローニングベクター
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 食料と農業
    • 市場動向
    • 市場予測
  • 健康と疾患
    • 市場動向
    • 市場予測
  • 環境
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • バイオテクノロジーおよび製薬企業
    • 市場動向
    • 市場予測
  • 学術機関および政府調査機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc
    • Cibus
    • F.Hoffmann-La Roche Ltd
    • GenScript
    • GlaxoSmithKline plc.
    • Horizon Discovery Group plc
    • Merck KGaA
    • New England Biolabs
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi S.A
    • Syngene International Ltd（Biocon Limited）
図表

List of Figures

  • Figure 1: Global: Recombinant DNA Technology Market: Major Drivers and Challenges
  • Figure 2: Global: Recombinant DNA Technology Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Recombinant DNA Technology Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Recombinant DNA Technology Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Recombinant DNA Technology Market: Breakup by Component (in %), 2023
  • Figure 6: Global: Recombinant DNA Technology Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Recombinant DNA Technology Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Recombinant DNA Technology Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Recombinant DNA Technology (Medical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Recombinant DNA Technology (Medical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Recombinant DNA Technology (Non-Medical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Recombinant DNA Technology (Non-Medical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Recombinant DNA Technology (Expression System) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Recombinant DNA Technology (Expression System) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Recombinant DNA Technology (Cloning Vector) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Recombinant DNA Technology (Cloning Vector) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Recombinant DNA Technology (Food and Agriculture) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Recombinant DNA Technology (Food and Agriculture) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Recombinant DNA Technology (Health and Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Recombinant DNA Technology (Health and Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Recombinant DNA Technology (Environment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Recombinant DNA Technology (Environment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Recombinant DNA Technology (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Recombinant DNA Technology (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Recombinant DNA Technology (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Recombinant DNA Technology (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Recombinant DNA Technology Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Recombinant DNA Technology Industry: SWOT Analysis
  • Figure 81: Global: Recombinant DNA Technology Industry: Value Chain Analysis
  • Figure 82: Global: Recombinant DNA Technology Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Recombinant DNA Technology Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Recombinant DNA Technology Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Recombinant DNA Technology Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 4: Global: Recombinant DNA Technology Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Recombinant DNA Technology Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Recombinant DNA Technology Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Recombinant DNA Technology Market: Competitive Structure
  • Table 8: Global: Recombinant DNA Technology Market: Key Players
目次
Product Code: SR112024A4484

The global recombinant DNA technology market size reached US$ 764.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,119.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032. The ongoing advancements in genetic engineering and biotechnology, the growing demand for biopharmaceuticals, increasing shift towards personalized medicines, and the rising prevalence of chronic diseases are primarily driving the market's growth.

Recombinant DNA Technology Market Analysis:

  • Major Market Drivers: The rising demand for improving different health conditions coupled with the improving treatment strategies on account of the developing diagnostics kits, monitoring devices, and new therapeutic approaches, represents one of the key factors impelling the growth of the market.
  • Key Market Trends: Rapid urbanization, growing global population, reducing arable land, considerable rising food shortage, and increasing adoption of GMO crops, are escalating the market demand. In addition, the integration of recombinant DNA technology with effective gene therapy for replacing defective genes with normal ones and the production of antigen-specific antibodies for clinical research, studies, and disease diagnosis, are anticipated to drive the market growth in the upcoming years.
  • Competitive Landscape: Some of the prominent recombinant DNA technology market companies include Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A, and Syngene International Ltd (Biocon Limited), among many others.
  • Geographical Trends: According to the recombinant DNA technology market dynamics, North America holds a prominent share in the recombinant DNA technology market, driven by extensive research and development activities, well-established healthcare infrastructure, and significant government funding. Moreover, the growth in Europe is supported by a strong focus on research and development and high adoption of biopharmaceuticals.
  • Challenges and Opportunities: Rising regulatory compliances and high competition among key players are hampering the market growth. However, there is an increasing demand for environmentally friendly and fuel-efficient landing gear systems. Manufacturers can capitalize on this trend by developing lightweight materials and energy-efficient designs.

Recombinant DNA Technology Market Trends:

Rising Demand for Biopharmaceuticals

The rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and insulin, is a major driver. For instance, according to IMARC, the global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. Recombinant DNA technology is pivotal in the production of these products, which are essential for treating various chronic diseases. These factors are expected to propel the recombinant DNA technology market in the coming years.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is one of the significant factors driving the market's growth. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 suffer from diabetes. Also, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Recombinant DNA technology enables the production of essential therapeutic proteins and hormones, such as insulin for diabetes management and erythropoietin for anemia treatment. These factors are further positively influencing the recombinant DNA technology industry market.

Technological Advancements

Continuous technological innovations, such as CRISPR and other gene-editing tools, are enhancing the precision and application scope of recombinant DNA technology, driving the market expansion. For instance, in August 2024, a group of German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors. CRISPR is a unique technology that enables geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences, thereby boosting the recombinant DNA technology systems market revenue.

Global Recombinant DNA Technology Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global recombinant DNA technology market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, component, application, and end user.

Breakup by Product:

  • Medical
    • Therapeutic Agent
    • Human Protein
    • Vaccines
  • Non-Medical
    • Biotech Crops
    • Specialty Chemicals
    • Others

The report has provided a detailed breakup and analysis of the recombinant DNA technology market based on the product. This includes medical (therapeutic agent, human protein, and vaccines), and non-medical (biotech crops, specialty chemicals, and others).

According to the recombinant DNA technology market outlook, recombinant DNA technology enables the development of gene therapies to treat genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy. This technology has revolutionized the production of human insulin, making it more accessible for diabetic patients. While crops like Bt cotton, Roundup Ready soybeans, and Golden Rice have been developed using rDNA technology to enhance resistance to pests, herbicides, and to improve nutritional content.

Breakup by Component:

  • Expression System
  • Cloning Vector

The report has provided a detailed breakup and analysis of the recombinant DNA technology market based on the component. This includes expression system and cloning vector.

According to the recombinant DNA technology market overview, an expression system refers to the host organism and the molecular machinery used to produce recombinant proteins. It includes the host cells, the vectors, and the regulatory sequences necessary for gene expression. While a cloning vector is a DNA molecule used to carry foreign genetic material into a host cell, where it can be replicated and/or expressed. It is used in the development of genetically modified crops with desirable traits such as pest resistance and improved nutritional content.

Breakup by Application:

  • Food and Agriculture
  • Health and Disease
  • Environment
  • Others

A detailed breakup and analysis of the recombinant DNA technology market based on application has also been provided in the report. This includes food and agriculture, health and disease, environment, and others.

Recombinant DNA technology is used to develop genetically modified (GM) crops with desirable traits such as increased yield, pest resistance, herbicide tolerance, and improved nutritional content. This is crucial for meeting the food demands of a growing global population. Apart from this, in health and disease, it enables the production of insulin, growth hormones, monoclonal antibodies, and vaccines. The demand for effective and affordable biopharmaceuticals drives this sector. Besides this, it is also used to engineer microorganisms that can break down pollutants and toxins in the environment. This helps in cleaning up oil spills, heavy metals, and other environmental contaminants.

Breakup by End User:

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Others

A detailed breakup and analysis of the recombinant DNA technology market based on end user has also been provided in the report. This includes biotechnology and pharmaceutical companies, academic and government research institutes, and others.

In biotechnology and pharmaceutical companies, recombinant DNA technology is used to produce human insulin in bacteria, which is a major advancement over previous methods using animal insulin. Companies use rDNA to develop monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. While government research institutes like the CDC use rDNA technology to monitor and study pathogens, enabling rapid response to outbreaks and epidemics.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the recombinant DNA technology market statistics, North America is one of the prominent regions for rDNA technology due to significant investments in biotechnology and pharmaceuticals. Moreover, Europe has a well-established biotechnology sector, particularly in countries like Germany, France, and the UK. The growth of the European region is driven by the strong collaboration between academic institutions, research institutes, and industry.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Amgen Inc
  • Cibus
  • F.Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • New England Biolabs
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A
  • Syngene International Ltd (Biocon Limited)

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recombinant DNA Technology Market Recent Developments:

  • August 2024: German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors.
  • July 2024: Scientists at the CSIR-Institute of Genomics and Integrative Biology in New Delhi developed an upgraded genome-editing device that can modify DNA more precisely and efficiently.
  • February 2024: Belgian researchers from the VIB-KU Leuven Center for Microbiology and the VIB-UGent Center for Plant Systems Biology created a new toolbox comprising 16 different short DNA sequences that may initiate controlled and selective recombination processes in any genome.

Key Questions Answered in This Report:

  • How has the global recombinant DNA technology market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global recombinant DNA technology market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global recombinant DNA technology market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Recombinant DNA Technology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Medical
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Therapeutic Agent
      • 6.1.2.2 Human Protein
      • 6.1.2.3 Vaccines
    • 6.1.3 Market Forecast
  • 6.2 Non-Medical
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Biotech Crops
      • 6.2.2.2 Specialty Chemicals
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Component

  • 7.1 Expression System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloning Vector
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Food and Agriculture
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Health and Disease
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Environment
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Biotechnology and Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Government Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Cibus
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 F.Hoffmann-La Roche Ltd
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 GenScript
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 GlaxoSmithKline plc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Horizon Discovery Group plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 New England Biolabs
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novo Nordisk A/S
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Syngene International Ltd (Biocon Limited)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis